# ORTHOCON

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orthocon

- Industry: Medical Devices & Equipment
- Headquarters: Irvington, US
- Website: www.orthocon.com
- Total disclosed funding: $35M
- Latest round: Series B (Apr 8, 2009)
- Investors on record: 5

## About

ORTHOCON, Inc. is a medical technology company focused on developing surgical therapeutic devices aimed at enhancing patient outcomes while improving surgical efficiency and safety for healthcare providers.ORTHOCON, Inc. specializes in the development and manufacturing of surgical devices. In April 2013, ORTHOCON, Inc. merged with Doctors Research Group, Inc. to form Abyrx, Inc. The company is headquartered in Irvington, US. The merger brought together expertise and resources to strengthen their market position. The company has received funding totaling USD 2.16 mn, with the most recent investment round led by Canaan Partners.ORTHOCON, Inc. develops and manufactures innovative surgical therapeutic devices that enhance patient outcomes. Their flagship product line, MONTAGE®, focuses on improving surgical application efficiency and safety, addressing critical needs in surgical environments. These products are utilized in hospitals and surgical centers across North America and Europe, catering to surgeons and medical professionals.ORTHOCON, Inc. generates revenue through direct sales of its surgical devices, primarily serving healthcare providers through contracts with hospitals and surgical centers. Their pricing structure reflects the advanced technology of MONTAGE® devices, though specific pricing details are not disclosed. The company also partners with distributors to broaden its market reach.With the recent funding of USD 2.16 mn, ORTHOCON, Inc. plans to enhance and expand its product line, focusing on new surgical devices and solutions designed for efficiency and precision. The company is targeting expansion into new markets within Europe and Asia by 2015, striving to meet the increasing demand for advanced surgical technologies. The investment aims to support product development and market entry initiatives.

## Funding rounds

- Series B, Apr 8, 2009, $25M — Canaan Partners, BB Biotech, ProQuest Investments
- Series A, Feb 23, 2006, $10M — Canaan Partners, Bellevue Group, Rockport Venture Partners

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- Bellevue Group — Series A
- Rockport Venture Partners — Series A
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series B
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series B